Shopping Cart
Remove All
Your shopping cart is currently empty
Rilotumumab (Synonyms: AMG 102)
Catalog No. T76758 Copy Product Info
🥰Excellent
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.
Rilotumumab
Copy Product Info🥰Excellent
Catalog No. T76758
Synonyms AMG 102
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.
Rilotumumab
Cas No. 872514-65-3
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $255 | In Stock | In Stock | |
| 5 mg | $668 | In Stock | In Stock | |
| 10 mg | $1,070 | - | In Stock | |
| 25 mg | $1,580 | - | In Stock | |
| 50 mg | $2,130 | - | In Stock | |
| 100 mg | $2,880 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.51% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer. |
| In vitro | In an overnight treatment at 10 μg/mL, Rilotumumab induces a decrease in MET phosphorylation at Y1234 and Y1235, accompanied by an increase in total MET[2]. |
| In vivo | In vivo, treatment with Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once every two days; for 11 days) inhibits glioma cell growth[2]. |
| Synonyms | AMG 102 |
| Reactivity | Human |
| Verified Activity | Immobilized Human HGF Protein (His) at 2 μg/mL (30 μL/well) can bind Rilotumumab. The EC50 is 25.07 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | HGF/SF |
| Molecular Weight | 145.2 kDa |
| Cas No. | 872514-65-3 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Rilotumumab | purchase Rilotumumab | Rilotumumab cost | order Rilotumumab | Rilotumumab in vivo | Rilotumumab in vitro | Rilotumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.